The new therapeutic frontier - Nuclear receptors and the liver

Journal of Hepatology

Volumn 52, Issue 3, 2010, Pages 455-462

  Karpen, Saul J ^a   Trauner, Michael ^b  

^a Division of Maternal Fetal Medicine   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Abbreviations; androgen receptor; AR (NR3C4); BA; bile acid; CAR (NR1I3); Cholestasis; constitutive androstane receptor; DKO; double knockout; ER (NR3A1); estrogen receptor; FA; farnesoid X receptor bile acid receptor; fatty acid; Fatty liver; FGF; fibroblast growth factor; Fibrosis; FXR (NR1H4); Gene expression; genome wide association study; glucocorticoid receptor; GR (NR3C1); GWAS; HBV; HCC; HCV; hepatic stellate cells; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; hepatocyte nuclear factor; HNF; HSC; ICP; intrahepatic cholestasis of pregnancy; Ligand; liver receptor homolog 1; LRH 1 (NR5A2); microsomal transfer protein; MTP; NAFLD; non alcoholic fatty liver disease; NR; nuclear (hormone) receptor; Nuclear receptor; PBC; peroxisomal proliferator activated receptor alpha; peroxisomal proliferator activated receptor gamma; PPAR (NR1C1); PPAR (NR1C3); pregnane X receptor; primary biliary cirrhosis; primary sclerosing cholangitis; PSC; PXR (NR1I2); RAR (NR1B1); retinoic acid receptor; retinoid X receptor; RXR (NR2B1); short heterodimer partner; SHP (NR0B2); VDR (NR1I2); vitamin D receptor; WAT; white adipose tissue

Indexed keywords

CELL NUCLEUS RECEPTOR; DNA BINDING PROTEIN; GLITAZONE DERIVATIVE; GLUCOCORTICOID; RIFAMPICIN;

CHOLESTASIS; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DNA BINDING; FATTY LIVER; HUMAN; INTRACELLULAR MEMBRANE; LIVER; LIVER CELL; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SCIENTIST; TRANSCRIPTION REGULATION; VIRUS HEPATITIS;

HUMANS; INFLAMMATION; LIPID METABOLISM; LIVER; LIVER DISEASES; LIVER REGENERATION; METABOLIC DETOXICATION, DRUG; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 77549083014     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.12.002     Document Type: Conference Paper

References (58)

1. Chambon P. How I became one of the fathers of a superfamily. Nat Med 10 (2004) 1027-1031
2. Evans R.M. The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 19 (2005) 1429-1438
3. Robinson-Rechavi M., Escriva Garcia H., and Laudet V. The nuclear receptor superfamily. J Cell Sci 116 (2003) 585-586
4. Nagy L., Schule R., and Gronemeyer H. Twenty years of nuclear receptors: conference on nuclear receptors: from chromatin to disease. EMBO Rep 7 (2006) 579-584
5. Gronemeyer H., Gustafsson J.-A., and Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3 (2004) 950-964
6. Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318 (1985) 635-641
7. Karpen S.J. Nuclear receptor regulation of hepatic function. J Hepatol 36 (2002) 832-850
8. Zollner G., and Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 156 (2009) 7-27
9. Stahl S., Davies M.R., Cook D.I., and Graham M.J. Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis. Xenobiotica 38 (2008) 725-777
10. Bookout A.L., Jeong Y., Downes M., Yu R.T., and Evans R.M. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126 (2006) 789-799
11. Yang X., Downes M., Yu R.T., Bookout A.L., He W., Straume M., Mangelsdorf D.J., et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 126 (2006) 801-810
12. Perissi V., and Rosenfeld M.G. Controlling nuclear receptors: the circular logic of cofactor cycles. Nat Rev Mol Cell Biol 6 (2005) 542-554
13. Baek S.H., and Rosenfeld M.G. Nuclear receptor coregulators: their modification codes and regulatory mechanism by translocation. Biochem Biophys Res Commun 319 (2004) 707-714
14. Rosenfeld M.G., and Glass C.K. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276 (2001) 36865-36868
15. Han S.J., Lonard D.M., and O'Malley B.W. Multi-modulation of nuclear receptor coactivators through posttranslational modifications. Trends Endocrinol Metab 20 (2009) 8-15
16. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 58 (2006) 760-772
17. Alenghat T., Meyers K., Mullican S.E., Leitner K., Adeniji-Adele A., Avila J., et al. Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456 (2008) 997-1000
18. Peter K., Rahel K., Jacqueline R., Ulrike K., Juan Francisco M., Flavio N., et al. Variation of the gene encoding the nuclear bile salt receptor FXR, gallstone susceptibility in mice, humans. J Hepatol 48 (2008) 116
19. Marzolini C., Tirona R.G., Gervasini G., Poonkuzhali B., Assem M., Lee W., et al. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol 21 (2007) 1769-1780
20. Semple R.K., Chatterjee V.K., and O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 116 (2006) 581-589
21. Vogel A., Strassburg C.P., and Manns M.P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35 (2002) 126-131
22. Altshuler D., Daly M.J., and Lander E.S. Genetic mapping in human disease. Science 322 (2008) 881-888
23. Hirschhorn J.N. Genomewide association studies - illuminating biologic pathways. N Engl J Med 360 (2009) 1699-1701
24. Tregouet D.A., Konig I.R., Erdmann J., Munteanu A., Braund P.S., Hall A.S., et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41 (2009) 283-285
25. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359 (2008) 1995-2004
26. Chopra A.R., Louet J.F., Saha P., An J., Demayo F., Xu J., et al. Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science 322 (2008) 1395-1399
27. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
28. Postic C., and Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118 (2008) 829-838
29. Trauner M. A little orphan runs to fat: the orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism. Hepatology 46 (2007) 1-5
30. Tontonoz P., and Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77 (2008) 289-312
31. Tan C.Y., and Vidal-Puig A. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans 36 (2008) 935-940
32. Medina-Gomez G., Gray S.L., Yetukuri L., Shimomura K., Virtue S., Campbell M., et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 3 (2007) e64
33. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58 (2006) 726-741
34. Nakajima T., Kamijo Y., Tanaka N., Sugiyama E., Tanaka E., Kiyosawa K., et al. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 40 (2004) 972-980
35. Moore D.D. Physiology. Sister act. Science 316 (2007) 1436-1438
36. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., and Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7 (2008) 678-693
37. Huang J., Iqbal J., Saha P.K., Liu J., Chan L., Hussain M.M., et al. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology 46 (2007) 147-157
38. Wang L., Huang J., Saha P., Kulkarni R.N., Hu M., Kim Y., et al. Orphan receptor small heterodimer partner is an important mediator of glucose homeostasis. Mol Endocrinol 20 (2006) 2671-2681
39. Zhang Y., Xu P., Park K., Choi Y., Moore D.D., and Wang L. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 48 (2008) 289-298
40. He N., Park K., Zhang Y., Huang J., Lu S., and Wang L. Epigenetic inhibition of nuclear receptor small heterodimer partner is associated with and regulates hepatocellular carcinoma growth. Gastroenterology 134 (2008) 793-802
41. Lee Y.K., and Moore D.D. Liver receptor homolog-1, an emerging metabolic modulator. Front Biosci 13 (2008) 5950-5958
42. Hunt A.N. Dynamic lipidomics of the nucleus. J Cell Biochem 97 (2006) 244-251
43. Wada T., Gao J., and Xie W. PXR and CAR in energy metabolism. Trends Endocrinol Metab 20 (2009) 273-279
44. Wagner M., Zollner G., and Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 51 (2009) 565-580
45. Alvaro D., Mancino M.G., Onori P., Franchitto A., Alpini G., Francis H., et al. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 12 (2006) 3537-3545
46. Scholtes C., Diaz O., Icard V., Kaul A., Bartenschlager R., Lotteau V., et al. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. J Hepatol 48 (2008) 192-199
47. Ramiere C., Scholtes C., Diaz O., Icard V., Perrin-Cocon L., Trabaud M.A., et al. Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXRalpha. J Virol 82 (2008) 10832-10840
48. Marra F., Efsen E., Romanelli R.G., Caligiuri A., Pastacaldi S., Batignani G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119 (2000) 466-478
49. Pinzani M., Rombouts K., and Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42 (2005) S22-S36
50. Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008;12:939-962, xi.
51. Fickert P., Fuchsbichler A., Moustafa T., Wagner M., Zollner G., Halilbasic E., et al. Farnesoid X Receptor (FXR) critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175 (2009) 2392-2405
52. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312 (2006) 233-236
53. Houten S.M. Homing in on bile acid physiology. Cell Metab 4 (2006) 423-424
54. Marschall H.U., Wagner M., Zollner G., Fickert P., Diczfalusy U., Gumhold J., et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129 (2005) 476-485
55. Wagner M., Halilbasic E., Marschall H.U., Zollner G., Fickert P., Langner C., et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42 (2005) 420-430
56. Fickert P., and Trauner M. When lightning strikes twice. the plot thickens for a dual role of the anion exchanger 2 (AE2/SLC4A2) in the pathogenesis and treatment of primary biliary cirrhosis. J Hepatol 50 (2009) 633-635
57. de Lera A.R., Bourguet W., Altucci L., and Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 6 (2007) 811-820
58. Wagner M., Zollner G., and Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology 48 (2008) 1383-1386